Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.144 CAD
−69.11 M CAD
0.00 CAD
47.46 M
About Aptose Biosciences, Inc.
Sector
CEO
William G. Rice
Headquarters
Toronto
Website
Founded
1986
FIGI
BBG00JVRKXM5
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
Aptos Biosciences APTO - Testing critical supportThis level should provide substantial support for a possible bounce. The risk/reward here is favorable for a long. Stop loss is essential, as always.
APTO Technical Analysis 🧙Aptose Biosciences Inc is a biotechnology company. It develops targeted medicines and personalized therapies for the precision treatment of life-threatening cancers such as acute myeloid leukemia, myelodysplastic syndromes and other hematologic malignancies and also therapies for Oncology. The firm
APTO Technical Analysis 🧙Aptose Biosciences Inc is a biotechnology company. It develops targeted medicines and personalized therapies for the precision treatment of life-threatening cancers such as acute myeloid leukemia, myelodysplastic syndromes and other hematologic malignancies and also therapies for Oncology. The firm
APTO Technical Analysis. 🧙Aptose Biosciences Inc is a biotechnology company. It develops targeted medicines and personalized therapies for the precision treatment of life-threatening cancers such as acute myeloid leukemia, myelodysplastic syndromes and other hematologic malignancies and also therapies for Oncology. The firm
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 0UI8 is 0.256 CAD — it has decreased by −80.81% in the past 24 hours. Watch APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) stocks are traded under the ticker 0UI8.
We've gathered analysts' opinions on APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) future price: according to them, 0UI8 price has a max estimate of 2.79 CAD and a min estimate of 2.79 CAD. Watch 0UI8 chart and read a more detailed APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) stock forecast: see what analysts think of APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) and suggest that you do with its stocks.
0UI8 reached its all-time high on Mar 24, 2021 with the price of 1,669.500 CAD, and its all-time low was 0.256 CAD and was reached on Nov 25, 2024. View more price dynamics on 0UI8 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0UI8 stock is 421.06% volatile and has beta coefficient of −0.85. Track APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) stock price on the chart and check out the list of the most volatile stocks — is APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) there?
Today APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) has the market capitalization of 16.07 M, it has decreased by −46.00% over the last week.
Yes, you can track APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) financials in yearly and quarterly reports right on TradingView.
APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) is going to release the next earnings report on Mar 25, 2025. Keep track of upcoming events with our Earnings Calendar.
0UI8 earnings for the last quarter are −0.50 CAD per share, whereas the estimation was −0.87 CAD resulting in a 42.19% surprise. The estimated earnings for the next quarter are −0.50 CAD per share. See more details about APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) earnings.
APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) revenue for the last quarter amounts to 0.00 CAD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
0UI8 net income for the last quarter is −9.48 M CAD, while the quarter before that showed −9.92 M CAD of net income which accounts for 4.42% change. Track more APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) financial stats to get the full picture.
No, 0UI8 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 11, 2024, the company has 35.00 employees. See our rating of the largest employees — is APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) on this list?
Like other stocks, 0UI8 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) stock shows the sell signal. See more of APTOSE BIOSCIENCES INC COM NPV(POST REV SPLIT) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.